

## Putting NICE guidance into practice

# **Implementing the NICE guidance on Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)**

Published: March 2014

The commissioner for this technology is NHS England.

The guidance on 'Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis' (NICE technology appraisal guidance 308) is estimated to cost approximately £1.1 million per annum.

However, because rituximab is already routinely funded by NHS England for most people for whom this technology is recommended by the NICE guidance, costs are not expected to be significant.